Olaf Van Tellingen
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 99 publications
Development and validation of an LC-MS/MS method for the quantification of the KRASG12C inhibitor divarasib.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
Published: April 03, 2026
Histidine to glutamine substitutants, a regulated process that impacts cell survival and suggests histidine shortage in cancer.
Journal: Cell death discovery
Published: February 23, 2026
Daraxonrasib (RMC-6236) pharmacokinetics: impact of transporters and drug-metabolizing enzymes on a first-in-class pan-RAS molecular glue.
Journal: Pharmacological research
Published: February 05, 2026
Antiretroviral raltegravir, a selective human immunodeficiency virus type 1 integrase inhibitor, shows anti-Alzheimer's potential against amyloid-beta1-42-induced neurodegeneration.
Journal: Mechanisms of ageing and development
Published: October 29, 2025
Arginine Deprivation of ASS1-Deficient Cancers Drives Mistranslation and Shared Neoepitope Production.
Journal: Cancer research
Published: October 21, 2025
Cranial radiotherapy profoundly affects glia without inducing widespread cellular senescence.
Journal: Neuro-oncology
Published: June 16, 2025
Development and Validation of a Rapid and Simple LC-MS/MS Method for Quantification of the Anti-Microtubule, Anti-Cancer Agent ABT-751 in Human and Mouse Plasma and Mouse Tissues.
Journal: Biomedical chromatography : BMC
Published: April 03, 2025
Neuroprotective effects of SGLT2 inhibitors empagliflozin and dapagliflozin on Aβ1-42-induced neurotoxicity and neuroinflammation in cellular models of Alzheimer's disease.
Journal: Journal of Alzheimer's disease : JAD
Published: March 20, 2025
Disconnect between in vitro and in vivo efficacy of the MPS1 inhibitor NTRC 0066-0 against glioblastoma.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: November 28, 2024
Aberrant neural activity in the peritumoral cortex underlies the progression of tumor-associated seizures.
Journal: Nature communications
Published: November 04, 2024
A Repurposed Drug Selection Pipeline to Identify CNS-Penetrant Drug Candidates for Glioblastoma.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: October 25, 2024
Last Updated: 09/26/2026